Copyright
©The Author(s) 2019.
World J Gastroenterol. May 21, 2019; 25(19): 2327-2337
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2327
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2327
Table 1 Baseline characteristics of patients with and without post-admission progression to hepatic decompensation
Variable | Total (n = 135) | Patients | P-value | |
Without progression to HD (n = 92) | With progression to HD (n = 43) | |||
Males | 120 (88.9) | 82 (88.2) | 38 (90.5) | 0.7771 |
Age (yr) | 39.1 ± 10.6 | 36.6 ± 9.4 | 44.6 ± 11.2 | 0.0002 |
LC | 62 (45.9) | 20 (21.7) | 42 (97.7) | 0.0001 |
HBeAg–positive | 53 (39.3) | 38 (40.9) | 15 (35.7) | 0.3551 |
log HBV DNA (copies/mL) | 6.7 (5.6, 7.5) | 6.9 (5.9, 7.5) | 6.3 (4.2, 7.2) | 0.0443 |
Na+ (mmol/L) | 137.0 ± 2.9 | 136.9 ± 3.0 | 136.9 ± 2.8 | 0.9272 |
ALT (IU/L) | 680.0 (421.0, 1191.0) | 838.0 (495.5, 1333.5) | 469.0 (265.5, 725.5) | 0.0003 |
AST (IU/L) | 592.0 (313.0, 980.0) | 636.0 (369.0, 1212.5) | 502.5 (268.5, 760.0) | 0.0223 |
GGT (IU/L) | 145.0 (108.0, 223.0) | 145.0 (110.5, 221.5) | 145.5 (94.5, 225.0) | 0.8453 |
CHE (IU/L) | 3.9 ± 1.5 | 4.3 ± 1.4 | 3.2 ± 1.4 | 0.0002 |
TBil (μmol/L) | 174.1 (96.1, 288.7) | 153.7 (93.9, 283.5) | 160.7 (88.8, 250.5) | 0.9323 |
ALB (g/L) | 33.6 ± 4.9 | 34.4 ± 4.2 | 31.6 ± 5.2 | 0.0012 |
PA (mg/L) | 48.0 (35.0, 69.0) | 54.4 ± 25.4 | 49.4 ± 30.5 | 0.3293 |
BUN (mmol/L) | 3.9 (3.0, 4.6) | 3.8 (2.9, 4.4) | 4.5(3.3, 4.4) | 0.0103 |
Cr (μmol/L) | 74.0 (67.0, 83.0) | 74.0 (67.0, 84.0) | 73.0 (66.3, 82.0) | 0.5573 |
INR | 1.46 ± 0.18 | 1.45 ± 0.18 | 1.47 ± 0.16 | 0.5102 |
PTA (%) | 51.9 ± 5.5 | 51.6 ± 5.5 | 52.9 ± 5.5 | 0.2082 |
WBC (109/L) | 5.2 (3.18, 6.7) | 5.4 (3.9, 6.5) | 4.7 (3.8, 7.5) | 0.6133 |
PLT (109/L) | 120.2 ± 49.1 | 128.9 ± 49.5 | 100.9 ± 42.8 | 0.0022 |
MELD | 17.5 ± 3.8 | 17.5 ± 3.9 | 17.3 ± 3.7 | 0.8302 |
Table 2 Baseline characteristics of patients with and without post-admission progression to acute-on-chronic liver failure
Variable | Total (n = 164) | Patients | P-value | |
Without progression to ACLF (n = 135) | With progression to ACLF (n = 29) | |||
Males | 143 (87.2) | 120 (88.9) | 23 (79.3) | 0.2161 |
Age (yr) | 39.8 ± 10.1 | 39.1 ± 10.6 | 43.1 ± 11.1 | 0.0662 |
LC | 83 (50.6) | 62 (45.9) | 21 (72.4) | 0.0131 |
HBeAg–positive | 101 (61.6) | 82 (60.7) | 19 (65.5) | 0.6791 |
log HBV DNA (copies/mL) | 6.7 (5.6, 7.5) | 6.7 (5.5, 7.5) | 7.1 (6.4, 7.7) | 0.0383 |
Na+ (mmol/L) | 137.0 ± 2.9 | 137.1 ± 2.7 | 137.7 ± 2.9 | 0.8282 |
ALT (IU/L) | 724.5 (441.5, 1227.6) | 680.0 (421.0, 1191.0) | 833.0 (532.0, 1770.0) | 0.0563 |
AST (IU/L) | 628.0 (330.3, 1101.0) | 592.0 (313.0, 980.0) | 779.0 (426.5, 1411.0) | 0.0413 |
GGT (IU/L) | 139.5 (99.0, 210.8) | 145.0 (108.0, 223.0) | 111.0 (84.5, 162.5) | 0.0493 |
CHE (IU/L) | 4.0 ± 1.5 | 3.9 ± 1.5 | 4.1 ± 1.5 | 0.5332 |
TBil (μmol/L) | 174.1 (96.1, 288.7) | 155.1 (93.6, 272.9) | 211.7 (147.3, 340.9) | 0.0383 |
ALB (g/L) | 33.5 ± 4.8 | 33.6 ± 4.8 | 33.3 ± 5.5 | 0.7852 |
PA (mg/L) | 46.0 (31.3, 67.0) | 48.0 (35.0, 69.0) | 42.0 (26.5, 51.5) | 0.0413 |
BUN (mmol/) | 3.9 (3.0, 4.6) | 3.9 (3.0, 4.6) | 3.8 (3.2, 4.4) | 0.9233 |
Cr (μmol/L) | 73.0 (66.0, 82.0) | 74.0 (67.0, 83.0) | 71.0 (63.0, 77.5) | 0.0773 |
INR | 1.50 ± 0.21 | 1.46 ± 0.18 | 1.72 ± 0.24 | 0.0002 |
PTA (%) | 51.1 (45.8, 55.8) | 52.5 (48.1, 57.0) | 44.0 (41.0, 47.8) | 0.0003 |
WBC (109/L) | 5.4 (3.9, 6.8) | 5.2 (3.18, 6.7) | 5.7 (4.4, 6.8) | 0.2073 |
PLT (109/L) | 118.9 ± 47.8 | 120.2 ± 49.1 | 112.5 ± 41.5 | 0.4332 |
MELD | 17.9 ± 3.8 | 17.5 ± 3.8 | 19.8 ± 3.1 | 0.0032 |
Table 3 Univariate and multivariate analyses of risk factors associated with post-admission progression to hepatic decompensation
Variable | Univariate analysis | Multivariate analysis | ||||||
Β | OR | 95%CI | P-value | β | OR | 95%CI | P-value | |
Age | 0.077 | 1.080 | 1.038-1.123 | 0.000 | ||||
HBV DNA | -0.276 | 0.759 | 0.587-0.981 | 0.035 | ||||
ALT | -0.002 | 0.998 | 0.997-0.999 | 0.000 | -0.003 | 0.997 | 0.995-1.000 | 0.038 |
AST | -0.001 | 0.999 | 0.998-1.000 | 0.015 | ||||
CHE | -0.599 | 0.549 | 0.405-0.744 | 0.000 | ||||
ALB | -0.140 | 0.869 | 0.796-0.948 | 0.002 | ||||
BUN | 0.238 | 1.268 | 1.029-1.563 | 0.026 | ||||
PLT | -0.014 | 0.986 | 0.977-0.995 | 0.003 | ||||
LC | 5.019 | 151.2 | 19.6-1167.6 | 0.000 | 5.040 | 154.5 | 16.2-1469.0 | 0.000 |
Table 4 Univariate and multivariate analyses of risk factors associated with post-admission progression to acute-on-chronic liver failure
Variable | Univariate analysis | Multivariate analysis | ||||||
Β | OR | 95%CI | P-value | β | OR | 95%CI | P-value | |
MELD | 0.161 | 1.175 | 1.049-1.315 | 0.005 | 0.184 | 1.202 | 1.033-1.398 | 0.017 |
HBV DNA | 0.380 | 1.463 | 1.018-2.101 | 0.040 | ||||
AST | 0.001 | 1.001 | 1.000-1.002 | 0.013 | 0.001 | 1.001 | 1.000-1.002 | 0.021 |
PTA | -0.252 | 0.777 | 0.704-0.858 | 0.000 | -0.257 | 0.758 | 0.672-855 | 0.000 |
LC | 1.128 | 3.091 | 1.280-7.465 | 0.012 | 2.125 | 8.369 | 2.389-29.322 | 0.001 |
- Citation: Yuan L, Zeng BM, Liu LL, Ren Y, Yang YQ, Chu J, Li Y, Yang FW, He YH, Lin SD. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol 2019; 25(19): 2327-2337
- URL: https://www.wjgnet.com/1007-9327/full/v25/i19/2327.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i19.2327